{"changeSha256":"5ec5d2fce4c6db199eb440056e2acf3f09825e9cdcdb3937c974f3cb6bc28d53","changedAt":"2026-11-14","changedFields":[{"after":"Not an FDA-approved drug","before":"FDA compounding assessment in the cited records","field":"Status"},{"after":"A synthetic four-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found only a few small human reports and no studies in people with insomnia.","before":"A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.","field":"Profile summary"},{"after":"FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.","before":"FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.","field":"Evidence note"},{"after":"AEDG, Epithalon, Ala-Glu-Asp-Gly","before":"AEDG, Epithalon","field":"Related names"},{"after":"fda-epitalon-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-epitalon-briefing, fda-pcac-peptide-meeting-2026","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]","field":"Named organizations"},{"after":"name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing; summary: fda-epitalon-briefing; evidenceNote: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing; summary: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-epitalon-briefing","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/epitalon/versions/3/","version":3},"id":"profile:epitalon:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule.","peptideSlugs":["epitalon"],"previousChangeEvent":{"path":"/corrections/v1/profiles/epitalon/v2.json","sha256":"65f4662a208c8d4438e948bd060d3c6f153f3156dd002b2087eeeef894c0dbe4"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/epitalon/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-epitalon-briefing","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA briefing document for epitalon","url":"https://www.fda.gov/media/193345/download","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-notice-2026","name":"Federal Register · U.S. Department of Health and Human Services","sourceClass":"A","title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026","url":"https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"epitalon","type":"profile"}}
